PDSS2
All trans-polyprenyl-diphosphate synthase PDSS2
Also known as: bA59I9.3, C6orf210, COQ1B, DLP1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q86YH6
- Gene
- PDSS2
- Ensembl
- ENSG00000164494
- Chromosome
- 6
- Canonical length
- 399 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
The protein encoded by this gene is an enzyme that synthesizes the prenyl side-chain of coenzyme Q, or ubiquinone, one of the key elements in the respiratory chain. The gene product catalyzes the formation of all trans-polyprenyl pyrophosphates from isopentyl diphosphate in the assembly of polyisoprenoid side chains, the first step in coenzyme Q biosynthesis. Defects in this gene are a cause of coenzyme Q10 deficiency.[provided by RefSeq, Oct 2009]
Canonical amino-acid sequenceUniProt
399 residues, UniProt reviewed canonical sequence.
>Q86YH6|PDSS2
1 MNFRQLLLHL PRYLGASGSP RRLWWSPSLD TISSVGSWRG RSSKSPAHWN QVVSEAEKIV
61 GYPTSFMSLR CLLSDELSNI AMQVRKLVGT QHPLLTTARG LVHDSWNSLQ LRGLVVLLIS
121 KAAGPSSVNT SCQNYDMVSG IYSCQRSLAE ITELIHIALL VHRGIVNLNE LQSSDGPLKD
181 MQFGNKIAIL SGDFLLANAC NGLALLQNTK VVELLASALM DLVQGVYHEN STSKESYITD
241 DIGISTWKEQ TFLSHGALLA KSCQAAMELA KHDAEVQNMA FQYGKHMAMS HKINSDVQPF
301 IKEKTSDSMT FNLNSAPVVL HQEFLGRDLW IKQIGEAQEK GRLDYAKLRE RIKAGKGVTS
361 AIDLCRYHGN KALEALESFP PSEARSALEN IVFAVTRFSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PDSS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 25 nTPM
Expression across tissuesHPA
Tissue
- liver: 25 nTPM
- kidney: 20 nTPM
- adrenal gland: 17 nTPM
- salivary gland: 14 nTPM
- prostate: 14 nTPM
- heart muscle: 13 nTPM
Single-cell type
- myonuclei: 330 nCPM
- prostatic glandular cells: 295 nCPM
- thyrotrophs: 279 nCPM
- lactotrophs: 272 nCPM
- choroid plexus epithelial cells: 249 nCPM
- corticotrophs: 239 nCPM
Immune cell
- non-classical monocyte: 9.9 nTPM
- myeloid DC: 7 nTPM
- intermediate monocyte: 5.9 nTPM
- MAIT T-cell: 5.9 nTPM
- naive B-cell: 5.5 nTPM
- T-reg: 5.5 nTPM
Brain region
- choroid plexus: 15 nTPM
- cerebellum: 13 nTPM
- white matter: 13 nTPM
- cerebral cortex: 12 nTPM
- hypothalamus: 12 nTPM
- thalamus: 12 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PDSS2.
Disease | AllUniProt
Conditions PDSS2 is implicated in, by any mechanism.
- Coenzyme Q10 deficiency, primary, 3 (COQ10D3) MIM:614652
Disease | GeneticClinVar
6 pathogenic / likely-pathogenic of 283 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Coenzyme Q10 deficiency, primary, 3
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.13
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.47
- DepMap mean gene effect
- -0.13
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cerebellum development
- isoprenoid biosynthetic process
- regulation of body fluid levels
- ubiquinone biosynthetic process
Molecular functions
- all-trans-decaprenyl-diphosphate synthase activity
- all-trans-nonaprenyl-diphosphate synthase (geranyl-diphosphate specific) activity
- prenyltransferase activity
- protein heterodimerization activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PDSS2 as an antibody target. Whether an autoantibody or antibody against PDSS2 could matter depends on whether native PDSS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PDSS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PDSS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...